Question

I am a breastfeeding mother and i want to know if it is safe to use 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone? Is 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone safe for nursing mother and child? Does 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone extracts into breast milk? Does 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone has any long term or short term side effects on infants? Can 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone influence milk supply or can 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone decrease milk supply in lactating mothers?

2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone lactation summary

2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone is unsafe in breastfeeding
  • DrLact safety Score for 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone is 5 out of 8 which is considered Unsafe as per our analyses.
  • A safety Score of 5 indicates that usage of 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone may cause serious side effects in breastfed baby.
  • Our study of different scientific research indicates that 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone may cause moderate to high side effects or may affect milk supply in lactating mother.
  • Our suggestion is to use safer alternate options rather than using 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone .
  • It is recommended to evaluate the advantage of not breastfeeding while using 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone Vs not using 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone And continue breastfeeding.
  • While using 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone usage in lactation

Statin drugs do its action by inhibiting cholesterol synthesis. On latest update relevant data on breastfeeding was not found. Its high plasma protein binding makes excretion into breast milk unlikely. Ability to alter fat composition of breast milk is unknown which is important since infants are in need of high amounts of cholesterol for adequate brain development, cell membrane building and hormone and vitamin synthesis. Avoid taking it at least while exclusive breastfeeding. Atorvastatin is possibly the safest statin drug because a higher molecular weight that lowers excretion into breast milk even more extensively. For Pravastatin a minimal excretion has been reported. Simvastatin has a lowest oral bioavailability. Avoiding drug treatment for cholesterol as long as breastfeeding is desired would probably not harm long term result of disease. Continuing with a low fat containing diet is recommended.

Answer by DrLact: About 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone usage in lactation

No relevant published information exists on the use of 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone during breastfeeding. Because of a concern with disruption of infant lipid metabolism, the consensus is that 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone should not be used during breastfeeding. However, others have argued that children homozygous for familial hypercholesterolemia are treated with statins beginning at 1 year of age, that statins have low oral bioavailability, and risks to the breastfed infant are low, especially with rosuvastatin and pravastatin.[1] Until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.